首页> 外文期刊>The Journal of Pathology: Clinical Research >Combined epithelial marker analysis of tumour budding in stage II colorectal cancer
【24h】

Combined epithelial marker analysis of tumour budding in stage II colorectal cancer

机译:II期大肠癌肿瘤萌发的联合上皮标记分析

获取原文
       

摘要

Tumour budding predicts survival of stage II colorectal cancer (CRC) and has been suggested to be associated with epithelial‐to‐mesenchymal transition (EMT). However, the underlying molecular changes of tumour budding remain poorly understood. Here, we performed multiplex immunohistochemistry (mIHC) to phenotypically profile tumours using known EMT‐associated markers: E‐cadherin (adherence junctions), integrin β4 (ITGB4; basement membrane), ZO‐1 (tight junctions), and pan‐cytokeratin. A subpopulation of patients showed high ITGB4 expression in tumour buds, and this coincided with a switch of ITGB4 localisation from the basal membrane of intact epithelium to the cytoplasm of budding cells. Digital image analysis demonstrated that tumour budding with high ITGB4 expression in tissue microarray (TMA) cores correlated with tumour budding assessed from haematoxylin and eosin (H&E) whole sections and independently predicted poor disease‐specific survival in two independent stage II CRC cohorts (hazard ratio [HR] = 4.50 (95% confidence interval [CI] = 1.50–13.5), n = 232; HR = 3.52 (95% CI = 1.30–9.53), n = 72). Furthermore, digitally obtained ITGB4‐high bud count in random TMA cores was better associated with survival outcome than visual tumour bud count in corresponding H&E‐stained samples. In summary, the mIHC‐based phenotypic profiling of human tumour tissue shows strong potential for the molecular characterisation of tumour biology and for the discovery of novel prognostic biomarkers.
机译:肿瘤出芽可预测II期结直肠癌(CRC)的存活,并已被认为与上皮间质转化(EMT)相关。然而,肿瘤萌芽的潜在分子变化仍然知之甚少。在这里,我们使用已知的EMT相关标记物进行了多重免疫组织化学(mIHC)来对肿瘤进行表型分析:E-钙黏着蛋白(粘附连接),整联蛋白β4(ITGB4;基底膜),ZO-1(紧密连接)和泛细胞角蛋白。一小部分患者在肿瘤芽中显示出高ITGB4表达,这与ITGB4定位从完整上皮基底膜向出芽细胞的细胞质的转换相吻合。数字图像分析表明,组织微阵列(TMA)核心中具有高ITGB4表达的肿瘤出芽与从苏木精和曙红(H&E)整个切片评估的肿瘤出芽相关,并独立预测了两个独立的II期CRC队列的疾病特异性生存率低(危险比[HR] = 4.50(95%置信区间[CI] = 1.50–13.5),n = 232; HR = 3.52(95%CI = 1.30–9.53),n = 72)。此外,在相应的H&E染色样本中,以数字方式获得的ITGB4随机TMA核心中高芽数与存活结果的关联性要好于视觉肿瘤芽数。总之,基于mIHC的人类肿瘤组织表型分析显示出对肿瘤生物学的分子表征和发现新的预后生物标志物的强大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号